Clinical Product Development
Our FDA-grade animal cell source allows for multiplex genomic edits in the germline – multipotent stem cells – which naturally differentiate into therapeutic cell targets.
We conduct all phases of clinical product development, including cell engineering, prototype design and evaluation, cGMP manufacturing, as well as pre-and-clinical stage product evaluation.
Our peer markets include Neurodegenerative Disease Cell Therapy, Organ Products, Infectious Disease & Vaccines, Skin & Wound Care, and Contract Cell Line Manufacturers.
Science is challenging; why go it alone? Alexis Bio is always eager to work with partners and collaborators who share our vision for fundamentally changing how medicine works, fixing diseases, and helping patients.
Our Pipeline
Discovery
Market
Approval
Xeno-Skin® - Live Biotherapeutic Porcine Skin Xenotransplant
Xeno-Nerve® - Live Biotherapeutic Peripheral Nerve Xenotransplant
AB001 - Dopaminergic Neuronal Cell Replacement for Parkinson's Disease
AB002 - Epitope-Targeted, Species-Specific Monoclonal Antibodies
AB003 (HEPA-Filter) - Ex-vivo Liver Dialysis for Acute Liver Failure
AB004 - Pancreatic Islet Cell Replacement for Type I Diabetes
AB005 (Bio-U-Twin) -
Personalized Animal Model for Individualized Disease and Clinical Trial Research
AB006 - MHC Haplotype Matched T-Cells for Oncology and Immunotherapy
AB007 - Kidney Xenotransplant for End-Stage Renal Failure
AB008 - Myocardial Cell and Blood Vessel Replacement for Heart Disease